


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 8. (Cancelled).

9. (New) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R<sup>1</sup> represents branched C<sub>3-6</sub> alkyl, C<sub>3-5</sub> cycloalkyl or -C<sub>1-4</sub> alkylC<sub>3-4</sub> cycloalkyl;

R<sup>2</sup> represents halogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, cyano, amino or trifluoromethyl;

n represents 0, 1 or 2;

R<sup>3</sup> represents -X-aryl, -X-heteroaryl, -X-heterocyclyl, -X-aryl-aryl, -X-aryl-heteroaryl, -X-aryl-heterocyclyl, -X-heteroaryl-aryl, -X-heteroaryl-heteroaryl, -X-heteroaryl-heterocyclyl, -X-heterocyclyl-aryl, -X-heterocyclyl-heteroaryl or -X-heterocyclyl-heterocyclyl;

such that when R<sup>3</sup> represents -X-piperidinyl, -X-piperidinyl-aryl, -X-piperidinyl-heteroaryl or -X-piperidinyl-heterocyclyl said piperidinyl group is attached to X via a nitrogen atom;

wherein R<sup>3</sup> is attached to the phenyl group of formula (I) at the 3 or 4 position;

X represents a bond, O, CO, SO<sub>2</sub>, CH<sub>2</sub>O, OCH<sub>2</sub>, NR<sup>4</sup>, NR<sup>4</sup>CO or C<sub>1-6</sub> alkyl;

R<sup>4</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

wherein said aryl, heteroaryl or heterocyclyl groups of R<sup>3</sup> may be optionally substituted by one or more halogen, hydroxy, cyano, nitro, oxo, haloC<sub>1-6</sub> alkyl, haloC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, arylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>3-7</sub> cycloalkylcarbonyl, -COC<sub>1-6</sub>

alkyl, C<sub>1-6</sub> alkoxy carbonyl, arylC<sub>1-6</sub> alkyl, heteroarylC<sub>1-6</sub> alkyl, heterocyclylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, aryloxy, -CO-aryl, -CO-heterocyclyl, -CO-heteroaryl, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group NR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>CO-aryl, -NR<sup>15</sup>CO-heterocyclyl, -NR<sup>15</sup>CO-heteroaryl, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup> or -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup> groups, wherein R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl; or solvates thereof.

10. (New) A compound according to claim 9 which is:

4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-4-biphenylcarbonitrile;  
1-{4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-4-biphenyl}ethanone;  
1-(4-Biphenylcarbonyl)-4-cyclobutylhexahydro-1*H*-1,4-diazepine;  
{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}(phenyl)methanone;  
1-Cyclobutyl-4-{[4-(phenyloxy)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-({4-[(phenylmethyl)oxy]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4-tetrazol-1-yl]phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-({4-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4-(1,1-dioxido-4-thiomorpholinyl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-(Isopropyl)-4-{[4-(tetrahydro-2*H*-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-({4-[6-(trifluoromethyl)-3-pyridinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;  
6-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-cyanopyridine;

5-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-*N*-methyl-2-pyridinecarboxamide;

5-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-2-cyanopyridine;

5-(4-{[4-(1-Isopropyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-cyanopyridine;

*N*-Methyl-5-(4-{[4-(1-isopropyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-pyridinecarboxamide;

1-(1-Methylethyl)-4-({4-[2-(trifluoromethyl)-5-pyrimidinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-(1-Methylethyl)-4-({4-[6-(trifluoromethyl)-3-pyridazinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-(1-Methylethyl)-4-({4-[6-(trifluoromethyl)-3-pyridinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

*N,N*-Dimethyl-5-(4-{[4-(1-methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-2-pyridinecarboxamide;

6-(4-{[4-(1-Methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}phenyl)-3-pyridinecarbonitrile;

1-Cyclobutyl-4-({4-[6-(trifluoromethyl)-3-pyridazinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-({4-[2-(trifluoromethyl)-5-pyrimidinyl]phenyl}carbonyl)hexahydro-1*H*-1,4-diazepine;

4'-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]-3-biphenylcarboxamide;

1-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-(trifluoromethyl)-1*H*-pyrazole-4-carbonitrile;

1-({4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}methyl)-5-(trifluoromethyl)-2(1*H*)-pyridinone;

4'-{[4-(1-Methylethyl)hexahydro-1*H*-1,4-diazepin-1-yl]carbonyl}-4-biphenylcarbonitrile;

*N*-{4-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-*N*,4,6-trimethyl-2-pyrimidinamine;

1-Cyclobutyl-4-[(3'-fluoro-4-biphenyl)carbonyl]hexahydro-1*H*-1,4-diazepine;

1-Cyclobutyl-4-{{4-(2-pyridinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(3-pyridinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
4-{{4-{{4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl}carbonyl}phenyl}oxy)benzonitrile;  
1-Cyclobutyl-4-{{4-{{(phenyloxy)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(3,5-dimethyl-4-isoxazolyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-{{4-(3,5-Dimethyl-4-isoxazolyl)phenyl}carbonyl}-4-(1-methylethyl)hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(1,3-oxazol-5-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(2-ethyl-2*H*-tetrazol-5-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(1*H*-pyrrol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(3,5-dimethyl-1*H*-pyrazol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-{{(3,5-dimethyl-1*H*-pyrazol-1-yl)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{4-(4-morpholinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-(1-Methylethyl)-4-{{4-(4-morpholinyl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine hydrochloride  
1-Cyclobutyl-4-{{3-{{(phenyloxy)methyl}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{3-{{(3-pyridinylmethyl)oxy}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{3-{{(3-pyridinylmethyl)oxy}phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{{3-(5-methyl-1*H*-tetrazol-1-yl)phenyl}carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-{{3-{{4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl}carbonyl}phenyl}-2-pyrrolidinone;

*N*-{3-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-3-pyridinecarboxamide;  
*N*-{3-[(4-Cyclobutylhexahydro-1*H*-1,4-diazepin-1-yl)carbonyl]phenyl}-4-pyridinecarboxamide;  
1-Cyclobutyl-4-{[3-(3-pyridinyl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4'-(1,3-oxazol-2-yl)-4-biphenylyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4'-(2-methyl-1,3-oxazol-4-yl)-4-biphenylyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4'-(2-methyl-1,3-oxazol-5-yl)-4-biphenylyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4'-(5-methyl-1,2,4-oxadiazol-3-yl)-4-biphenylyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4-(1,3-oxazol-2-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-(1-Methylethyl)-4-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
1-Cyclobutyl-4-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl}hexahydro-1*H*-1,4-diazepine;  
or a pharmaceutically acceptable salt or solvate thereof.

11. (New) A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 9 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.

12. (New) A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 9 or a pharmaceutically acceptable salt or solvate thereof.